Allergic Rhinitis Immunotherapy: Opportunity Analysis and Forecasts to 2028

1.1 List of Tables
1.2 List of Figures

2.1 Modest Growth Expected for ASIT Market over Forecast Period (2018-2028)
2.2 ASIT Market Continues to Shift Toward SLIT and Short-Course SCIT Products
2.3 Lingering Unmet Needs Severely Limit ASIT Uptake and Persistence Among Patients with AR
2.4 Pipeline Short-Course, Preseasonal SCIT Products Utilize Both New and Old Approaches to Promote Allergen Desensitization
2.5 What Do Physicians Think?

3.1 Catalyst
3.2 Related Reports

4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification
4.2.1 Seasonal and Perennial AR
4.2.2 ARIA Classification of AR

5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for AR (2018-2028)
5.5.1 Diagnosed Incident Cases of AR
5.5.2 Age-Specific Diagnosed Incident Cases of AR
5.5.3 Sex-Specific Diagnosed Incident Cases of AR
5.5.4 12-Month Diagnosed Prevalent Cases of AR
5.5.5 Age-Specific 12-Month Diagnosed Prevalent Cases of AR
5.5.6 Sex-Specific 12-Month Diagnosed Prevalent Cases of AR
5.5.7 12-Month Diagnosed Prevalent Cases of AR by Severity
5.5.8 12-Month Diagnosed Prevalent Cases of AR by Type of Allergen
5.5.9 12-Month Total Prevalent Cases of AR
5.5.10 Age-Specific 12-Month Total Prevalent Cases of AR
5.5.11 Sex-Specific 12-Month Total Prevalent Cases of AR
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis

6.1 Overview
6.2 Diagnosis
6.3 Treatment Algorithm
6.3.1 Guidelines
6.3.2 OTC and Prescription Symptomatic Therapies
6.3.3 ASIT

7.1 Overview
7.2 Increased Patient Access to ASIT
7.2.1 Improved Insurance Coverage for ASIT Products
7.2.2 Increased Access to Physicians Trained to Administer ASIT
7.3 Changes to ASIT Regulation
7.4 Improved ASIT Compliance and Persistence

8.1 Overview
8.1.1 Improve Safety and Convenience Through Increased Use of SLIT
8.1.2 Speed Up SCIT While Maintaining Efficacy and Safety
8.1.3 Expand Product Use to New Indications: Asthma Treatment and Prophylaxis
8.2 Clinical Trials Design
8.2.1 Current Clinical Trial Design
8.2.2 Strategies for Study Participant Selection
8.2.3 Use of Controlled Challenge Endpoints in Earlier-Stage Trials
8.2.4 Clinically Relevant Trial Endpoints for Phase III Studies

9.1 Overview
9.2 Innovative Early-Stage Approaches
9.2.1 Mannan-Conjugated Allergoids
9.2.2 Contiguous Overlapping Peptides Allergy Vaccines
9.2.3 New Therapies for Cat Allergy
9.3 Other Drugs in Development

10.1 Clinical Benchmark of Key Pipeline Drugs
10.1.1 Grass Pollen SCIT
10.1.2 Tree Pollen SLIT
10.2 Commercial Benchmark of Key Pipeline Drugs
10.2.1 Grass Pollen SCIT
10.2.2 Tree Pollen SLIT
10.3 Competitive Assessment
10.3.1 Grass Pollen SCIT
10.3.2 Tree Pollen SLIT
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan

Table 1: Allergic Rhinitis Immunotherapy: Key Metrics in the 7MM
Table 2: Risk Factors and Comorbid Conditions Associated with AR
Table 3: 7MM, 12-Month Diagnosed Prevalent Cases of AR by Type of Allergen, N, Both Sexes, Ages =5 Years, 2018
Table 4: Popular Guidelines Available for Allergic Rhinitis and the Use of ASIT, 2019
Table 5: Examples of ASIT Product Up-Dosing Profiles, 2019
Table 6: NPT Protocols
Table 7: CPT Protocol - TOSS
Table 8: Standardized Scoring System for the CSMS
Table 9: Comparison of Pipeline Short Course SCIT Products for Grass Pollen
Table 10: Comparison of Pipeline SLIT Tablets for Tree Pollen Allergy
Table 11: Early-Stage Allergen Immunotherapy Candidates for Allergic Rhinitis, 2019
Table 12: Other ASIT Products in Development for AR, 2019
Table 13: Clinical Benchmark of Key SCIT Pipeline Drugs for Grass Pollen Allergy
Table 14: Clinical Benchmark of Key SLIT Pipeline Drugs for Tree Pollen Allergy
Table 15: Commercial Benchmark of Key SCIT Pipeline Drugs for Grass Pollen Allergy
Table 16: Commercial Benchmark of Key SLIT Pipeline Drugs for Tree Pollen Allergy
Table 17: Key Events Impacting Sales for Allergic Rhinitis Immunotherapy, 2018-2028
Table 18: Allergic Rhinitis Immunotherapy Market - Global Drivers and Barriers, 2018-2028
Table 19: Key Historical and Projected Launch Dates for Allergic Rhinitis Immunotherapy
Table 20: Key Historical and Projected Patent/Exclusivity Expiry Dates for Allergic Rhinitis Immunotherapy
Table 21: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global (7MM) Sales Forecast by Country for Allergic Rhinitis Immunotherapy in 2018 and 2028
Figure 2: Competitive Assessment of Grass Pollen SCIT Pipeline Drugs Benchmarked Against SOCs, Grass Pollen Bulk Extracts and Allergovit Grasses
Figure 3: Competitive Assessment of Tree Pollen SLIT Pipeline Drugs Benchmarked Against SOCs, Cedarcure and Staloral Birch
Figure 4: Examples of Inhaled Allergens that Can Cause AR
Figure 5: The Atopic March - Age at Diagnosis of Common Allergic Conditions
Figure 6: Hypersensitivity Reaction to Inhaled Allergens and Therapeutic Targets
Figure 7: Desensitization to Aeroallergens using ASIT
Figure 8: ARIA Classification of AR
Figure 9: 7MM, Diagnosed Incidence of AR (Cases per 100,000 Population), Men and Women, Ages =5 Years, 2018
Figure 10: 7MM, 12-Month Diagnosed Prevalence of AR (%), Men and Women, Ages =5 Years, 2018
Figure 11: 7MM, 12-Month Total Prevalence of AR (%), Men and Women, Ages =5 Years, 2018
Figure 12: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of AR
Figure 13: 7MM, Sources Used to Forecast the 12-Month Diagnosed Prevalent Cases of AR
Figure 14: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of AR
Figure 15: 7MM, Sources Used to Forecast the 12-Month Diagnosed Prevalent Cases of AR by Severity
Figure 16: 7MM, Diagnosed Incident Cases of AR, N, Both Sexes, =5 Years, 2018
Figure 17: 7MM, Age-Specific Diagnosed Incident Cases of AR, N, Both Sexes, Ages =5 Years, 2018
Figure 18: 7MM, Sex-Specific Diagnosed Incident Cases of AR, N, Ages =5 Years, 2018
Figure 19: 7MM, 12-Month Diagnosed Prevalent Cases of AR, N, Both Sexes, Ages =5 Years, 2018
Figure 20: 7MM, Age-Specific 12-Month Diagnosed Prevalent Cases of AR, N, Both Sexes, Ages =5 Years, 2018
Figure 21: 7MM, Sex-Specific 12-Month Diagnosed Prevalent Cases of AR, N, Ages =5 Years, 2018
Figure 22: 7MM, 12-Month Diagnosed Prevalent Cases of AR by Severity, N, Both Sexes, Ages =5 Years, 2018
Figure 23: 7MM, 12-Month Total Prevalent Cases of AR, N, Both Sexes, Ages =5 Years, 2018
Figure 24: 7MM, Age-Specific 12-Month Total Prevalent Cases of AR, N, Both Sexes, Ages =5 Years, 2018
Figure 25: 7MM, Sex-Specific 12-Month Total Prevalent Cases of AR, N, Ages =5 Years, 2018
Figure 26: ARIA Guidelines for the Treatment of AR
Figure 27: Projections for Future SCIT Use in the 7MM
Figure 28: Projections for Future SLIT Use in the 7MM
Figure 29: Common Allergens Targeted by ASIT Throughout the 7MM (Normalized to 100%)
Figure 30: ASIT - Line of Therapy
Figure 31: Comparing SCIT and SLIT - Preferred Therapy
Figure 32: Unmet Needs and Opportunities in Allergic Rhinitis Immunotherapy
Figure 33: Comparing SCIT and SLIT - Efficacy and Safety
Figure 34: Overview of the Development Pipeline of ASIT Products for AR
Figure 35: Key Phase II/III Trials for Promising Pipeline ASIT Products that GlobalData Expects to Be Licensed for AR in the 7MM During the Forecast Period, 2019
Figure 36: Opinions of US Physicians Regarding Use of Pre-formulated, Single-Allergen ASIT Products
Figure 37: Competitive Assessment of Grass Pollen SCIT Pipeline Drugs Benchmarked Against SOCs, Grass Pollen Bulk Extracts and Allergovit Grasses
Figure 38: Competitive Assessment of Tree Pollen SLIT Pipeline Drugs Benchmarked Against SOCs, Cedarcure and Staloral Birch
Figure 39: Global (7MM) Sales Forecast for Allergic Rhinitis Immunotherapy, 2018-2028
Figure 40: Global (7MM) Sales Forecast by Country for Allergic Rhinitis Immunotherapy in 2018 and 2028
Figure 41: Global Sales Forecast by Administration Method for Allergic Rhinitis Immunotherapy in 2018 and 2028
Figure 42: Global Sales Forecast by Company for Allergic Rhinitis Immunotherapy in 2018 and 2028
Figure 43: Sales Forecast by Administration Method for Allergic Rhinitis Immunotherapy in the US in 2018 and 2028
Figure 44: Sales Forecast by Company for Allergic Rhinitis Immunotherapy in the US in 2018 and 2028
Figure 45: Sales Forecast by Product for Allergic Rhinitis Immunotherapy in the US in 2018 and 2028
Figure 46: Sales Forecast by Country for Allergic Rhinitis Immunotherapy in the 5EU in 2018 and 2028
Figure 47: Sales Forecast by Administration Method for Allergic Rhinitis Immunotherapy in the 5EU in 2018 and 2028
Figure 48: Sales Forecast by Company for Allergic Rhinitis Immunotherapy in the 5EU in 2018 and 2028
Figure 49: Sales Forecast by Administration Method for Allergic Rhinitis Immunotherapy in Japan in 2018 and 2028
Figure 50: Sales Forecast by Company for Allergic Rhinitis Immunotherapy in Japan in 2018 and 2028
Figure 51: Sales Forecast by Product for Allergic Rhinitis Immunotherapy in Japan in 2018 and 2028